Skip to main content
main-content

Latest from Medicine Matters oncology

Latest headlines

19-05-2020 | Breast cancer | News

TAILORx sheds light on cognitive decline in early-stage breast cancer

An analysis of the TAILORx trial has revealed early, but not sustained, cognitive decline among breast cancer patients treated with adjuvant chemoendocrine therapy relative to endocrine therapy alone.

19-05-2020 | Comorbidities | News

More evidence for increased mortality risk in cancer patients with COVID-19

Patients with cancer and comorbid SARS-CoV-2 infection have elevated age-adjusted case fatality rates relative to COVID-19 patients without cancer, shows an analysis from a US hospital system.

18-05-2020 | Comorbidities | News

​​​​​​​ESMO-CoCARE cancer, COVID-19 registry launched

The ESMO-CoCARE registry has been initiated to better understand the impact of COVID-19 on people with cancer.

15-05-2020 | FDA | News

Selpercatinib receives FDA nod

Read more about this approval here

14-05-2020 | Durvalumab | News

Durvalumab feasible for cancer patients with HIV

Phase 2 trial results point to the feasibility of treatment with the PD-L1 inhibitor durvalumab in people with advanced solid cancer and controlled type 1 HIV infection.

13-05-2020 | EMA | News

EMA supports hybrid cabazitaxel formulation for mCRPC

Click here to read more

Feature content

20-04-2020 | Prostate cancer | Brief review | Article

Promising immunotherapies for advanced prostate cancer: playing catch-up?

Abhishek Srivastava and Neal Shore survey upcoming trials and promising new immunotherapies for advanced PCa, while highlighting some of the successes in PCa immunotherapy.

16-12-2019 | Renal cell carcinoma | Video | Article

Axel Merseburger: Recent developments in metastatic renal cell carcinoma

Axel Merseburger provides an overview of the most promising trials and biomarkers in renal cell carcinoma at ESMO 2019.

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA.

15-11-2019 | Renal cell carcinoma | At a glance | Article

At a glance: The IMmotion RCC trials

A quick-reference guide to the IMmotion trials evaluating the anti-PD-L1 agent atezolizumab for the treatment of renal cell carcinoma.

Get the latest content delivered to your inbox

Register with Medicine Matters to start receiving our weekly newsletter now!

Image Credits